ES2175400T3 - Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer. - Google Patents

Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer.

Info

Publication number
ES2175400T3
ES2175400T3 ES97920514T ES97920514T ES2175400T3 ES 2175400 T3 ES2175400 T3 ES 2175400T3 ES 97920514 T ES97920514 T ES 97920514T ES 97920514 T ES97920514 T ES 97920514T ES 2175400 T3 ES2175400 T3 ES 2175400T3
Authority
ES
Spain
Prior art keywords
disease
alzheimer
activated
lymphocytes
activation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97920514T
Other languages
English (en)
Inventor
Manfred Dr Hartwig
Jorg Prof Dr Schulz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCHULZ JORG PROF DR MED
Original Assignee
SCHULZ JORG PROF DR MED
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19608519A external-priority patent/DE19608519A1/de
Priority claimed from DE1996132671 external-priority patent/DE19632671A1/de
Priority claimed from DE1996140348 external-priority patent/DE19640348A1/de
Application filed by SCHULZ JORG PROF DR MED filed Critical SCHULZ JORG PROF DR MED
Application granted granted Critical
Publication of ES2175400T3 publication Critical patent/ES2175400T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCEDIMIENTO PARA DIAGNOSTICAR LA ENFERMEDAD DE ALZHEIMER Y ENFERMEDADES CON UNA ETIOLOGIA SIMILAR, ASI COMO A MEDIOS FARMACEUTICOS PARA SU TRATAMIENTO. LOS CAMPOS DE APLICACION DE LA INVENCION SON LA MEDICINA Y LA INDUSTRIA FARMACEUTICA. EL PUNTO DE PARTIDA DE LA INVENCION ES EL SORPRENDENTE DESCUBRIMIENTO DE QUE UN FACTOR CAUSANTE DE LA ENFERMEDAD DE ALZHEIMER ES LA PRODUCCION PATOLOGICA DE LINFOCITOS T ACTIVADOS AUTOESPECIFICOS EN LA SANGRE PERIFERICA. LOS LINFOCITOS T ACTIVADOS ATRAVIESAN LA BARRERA HEMATOENCEFALICA, SUCUMBEN FRENTE A LA APOPTOSIS AL ACTUAR JUNTO CON CELULAS DE LA MICROGLIA Y, CON LA ACTIVACION DE LA MICROGLIA, ACTIVAN EL PROCESO DE ENCENDIDO NEUROTOXICO CARACTERISTICO. EL PROCEDIMIENTO CONFORME A LA INVENCION UTILIZA UNA MUESTRA DE SANGRE PERIFERICA, A PARTIR DE LA CUAL SE DIAGNOSTICA LA ENFERMEDAD DE ALZHEIMER CON BASE EN LA PROPORCION DE CELULAS MONONUCLEARES APOPTOSICAS (MURIENTES), EN LA ACTIVACION DE MONOCITOS/MACROFAGOS O EN AMBOS METODOS EN COMBINACION. EL MEDIO CONFORME A LA INVENCION CONTIENE COMO SUSTANCIA ACTIVA UN FACTOR QUE AUMENTA LA ACTIVIDAD FAGOCITICA EN EL CUERPO Y EN UN ORGANO ESPECIFICO, EN ESPECIAL EN EL CEREBRO, O BIEN UNA SUSTANCIA QUE SE FIJA SELECTIVAMENTE A MARCADORES DE ACTIVACION O RECEPTORES DE ADHESION DE LINFOCITOS L ACTIVADOS O A RECEPTORES DE ADHESION DE CELULAS ENDOTELIALES.
ES97920514T 1996-03-06 1997-03-03 Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer. Expired - Lifetime ES2175400T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19608519A DE19608519A1 (de) 1996-03-06 1996-03-06 Mittel zur Therapie der Alzheimer-Krankheit und von Krankheiten analoger Ursache
DE1996132671 DE19632671A1 (de) 1996-08-14 1996-08-14 Verfahren zur Diagnostik der Alzheimer-Krankheit
DE1996140348 DE19640348A1 (de) 1996-09-20 1996-09-20 Mittel zur Therapie der Alzheimer-Krankheit

Publications (1)

Publication Number Publication Date
ES2175400T3 true ES2175400T3 (es) 2002-11-16

Family

ID=27215983

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97920514T Expired - Lifetime ES2175400T3 (es) 1996-03-06 1997-03-03 Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer.

Country Status (5)

Country Link
EP (1) EP0885392B1 (es)
AT (1) ATE213067T1 (es)
DE (1) DE59706309D1 (es)
ES (1) ES2175400T3 (es)
WO (1) WO1997033175A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
GB0802851D0 (en) 2008-02-15 2008-03-26 Medinnova As Diagnostic method
DE102009021553A1 (de) 2009-05-09 2010-11-18 Kettenbach Gmbh & Co. Kg Härtbare Zusammensetzungen, daraus hergestellte gehärtete Produkte und deren Verwendung
AU2011336895A1 (en) * 2010-11-24 2013-06-06 Elan Pharmaceuticals, Inc. Phagocytic activity as a marker of synucleinopathic disease

Also Published As

Publication number Publication date
ATE213067T1 (de) 2002-02-15
EP0885392B1 (de) 2002-02-06
DE59706309D1 (de) 2002-03-21
WO1997033175A1 (de) 1997-09-12
EP0885392A1 (de) 1998-12-23

Similar Documents

Publication Publication Date Title
Novak Post COVID-19 syndrome associated with orthostatic cerebral hypoperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report
Ruff et al. Auditory spatial deficits in the personal and extrapersonal frames of reference due to cortical lesions
Kosten Pharmacotherapy of cerebral ischemia in cocaine dependence
KR960700742A (ko) 아토피성질환 치료약(atopic disease remedy)
MA29346B1 (fr) Formulations pharmaceutiques gastrorésistantes à base de rifaximine
HUP0202779A2 (hu) Immunológiai eljárás szöveti transzglutamináz (tTG) elleni antitestek kimutatására, tTG alkalmazása diagnosztikai célokra és terápiás ellenőrzésre, valamint tTG-t tartalmazó orális gyógyászati hatóanyag
PT1135168E (pt) Vectores peptidicos de substancias atraves da barreira hemato-encefalica
BR9807055A (pt) Composição farmacêutica, uso de um agente fotoquimioterapêutico precursor da protoporfirina junto com um fotossensibilizador de localização de estroma vascular, produto contendo os mesmos, kit para uso em fotoquimioterapia de distúrbios ou anormalidades das superfìcies externa ou interna do corpo, e, processos de tratamento fotoquimioterapêutico de distúrbios ou anormalidades de superfìcies externa ou interna do corpo, e de diagnóstico in vitro de anormalidades ou distúrbios, mediante ensaios de uma amostra de fluidos corporais ou tecidos de um paciente
ES2175400T3 (es) Procedimiento para el diagnostico diferencial de los diferentes estadios de la enfermedad de alzheimer.
Sun et al. Ghrelin attenuates depressive-like behavior, heart failure, and neuroinflammation in postmyocardial infarction rat model
CA2154080A1 (en) Novel anticoagulant cofactor activity
DE69535876D1 (de) Nadh-oxidase als zielmolekül in diagnose und therapie
Krill et al. The effect of two hallucinogenic agents on human retinal function
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
Lamberg Symptomatic pitted keratolysis
Le Melledo et al. Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide
Astikainen et al. Somatosensory event-related potentials in the rabbit cerebral and cerebellar cortices: a correspondence with mismatch responses in humans
Friedmann et al. T cell-mediated neuroprotection involves antithrombin activity
Brenner et al. A possible case of drug-induced familial pemphigus
Marshall Quick Release of AIDS Drugs: In response to lobbying by patients, US health officials agree to distribute experimental AIDS drugs before testing for effectiveness is complete;" parallel track" to be ready by the fall
RU2510724C1 (ru) Способ диагностики генеза хронического простатита по типам реагирования микрососудистого эндотелия
IT1283899B1 (it) Peptidi e loro usi nella terapia della malattia celiaca
Drake Jr et al. Contingent negative variation in epilepsy
ES2162040T3 (es) Utilizacion de un conjugado de un agente citostatico y albumina para producir medicamentos antiinflamatorios.
Boyqo‘ziyeva Prognostic Significance and Advantage of Echocardiography in The Diagnosis of Ischemic Heart Disease

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 885392

Country of ref document: ES